This includes the design of more potent and selective SIRT1 modulators and the evaluation of their efficacy in preclinical models of diseases characterized by ferroptosis, such as kidney diseases, neurodegenerative disorders, and cancer. This evidence concerns the gene SIRT1 and cancer.